Jefferies initiates Candel Therapeutics at Buy with $25 target
Bullish analyst view, though the signal is based on a single analyst opinion and the target is not a forecast guarantee.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Bullish analyst view, though the signal is based on a single analyst opinion and the target is not a forecast guarantee.
What happened, with direct paths to the underlying reporting
Jefferies initiated coverage of CADL with a Buy rating and a $25 target versus the posted price of $8.37, indicating substantial analyst-implied upside.
Target: $25
Posted price: $8.37
Analyst firm: Jefferies
Analyst: Maury Raycroft
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.